Also known as aed, t‑31, alanyl‑glutamyl‑aspartate · Wikipedia
Cartalax is a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp (AED), developed by the Khavinson school at the St. Petersburg Institute of Bioregulation and Gerontology and marketed as a cartilage-and-connective-tissue 'bioregulator.' It belongs to the same family of ultra-short peptides as Epitalon (AEDG), Pinealon (EDR), and Vilon (KE), and is hypothesized to enter cells and bind directly to gene promoter regions in chondrocytes and fibroblasts to modulate transcription of collagen type II, aggrecan, and other extracellular-matrix components. Almost all published evidence is in Russian-language preclinical literature and cell culture; rigorous Western-style human trials are absent.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Cartalax (Ala-Glu-Asp, AED) is a Khavinson short-peptide bioregulator. The Khavinson hypothesis is that ultra-short peptides cross plasma and nuclear membranes and bind directly to specific promoter sequences in chondrocytes and fibroblasts, modulating transcription of cartilage-matrix genes including type II collagen and aggrecan.
Pharmacokinetic properties
Half-life
unknown - short peptides of this class are assumed to be rapidly cleared from plasma but to act via tissue-localized intracellular binding
Routes
subcutaneous · intramuscular · oral
Bioavailability
Khavinson short peptides are claimed to retain activity orally because of small size, but rigorous human bioavailability data are absent. Russian capsule formulations are sold for oral use.
Amino-acid sequence
Ala-Glu-Asp (AED)
Use & research dosing
Research framing only. Russian product monographs cite injectable courses of 5-10 mg subcutaneously or intramuscularly daily for 10-20 days, repeated every 3-6 months. Oral capsule formulations are sold at roughly 200-400 mcg per capsule taken once or twice daily for 1-3 month courses. None of these regimens have been validated in controlled human trials; they reflect manufacturer monograph recommendations rather than dose-finding studies. Oral bioavailability of such short peptides in humans is uncharacterized. Buyers should treat all circulating dose ranges as anecdotal.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Cartalax sits in the Khavinson 'bioregulator' family alongside Epitalon, Pinealon, Vilon, and the organ-targeted peptides (Cardiogen, Thymalin, Prostamax). The mechanistic claim - direct binding of ultra-short peptides to gene promoters - remains contested outside the St. Petersburg group, and Western preclinical and clinical replication is limited. Buyers should regard joint and cartilage support claims as preliminary. The compound is sold for both injectable and oral courses despite the absence of human pharmacokinetic data for either route.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.